<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487448</url>
  </required_header>
  <id_info>
    <org_study_id>SMD_FLAG-IDA_98</org_study_id>
    <nct_id>NCT00487448</nct_id>
  </id_info>
  <brief_title>SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia</brief_title>
  <acronym>FLAG-IDA</acronym>
  <official_title>FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Association group of therapeutic specialities authorized in a remission induction
      treatment(FLAG-IDA: fludarabine, cytarabine, G-CSF (lenograstim) and idarubicin) and an
      intensive postremission treatment with authorized therapeutic association specialities and
      with/without Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation
      in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic
      Leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To reach the first remission, the patients receive one cycle of FLAG-IDA combination, that
      include: Fludarabine 30 mg/m 2 /d Days 1 to 4 in IV perfusion during 30 minutes; Cytarabine 2
      g/m 2/d, days 1 to 4 in IV perfusion during 4 hours glycosylate G-CSF 300 µg/m 2/d, days -1
      to 5 SC; lenograstim 263 µg/d f, days 11 until absolute neutrophil count &gt;1x10 9 /L SC;
      Idarubicin 10 mg/m2/d, days 1 to 3 IV bolus (15 minutes)

      Patients who don't reach complete remission (CR) are considered as a failure and must go out
      of study.

      The participating centres should decide if the patients under 35 years in CR and with
      unrelated donor, are excluded to be treated with allogenic transplantation or they continue
      in the study.

      The patients who reach CR will receive one consolidation cycle with IDA-ARAC + G-CSF
      combination:

      Idarubicin 10 mg/m2/d, days 1 to 3 IV bolus (15 minutes); Cytarabine 200 mg/m 2/d days 1 to 5
      IV in 24 hours continuous perfusion; glycosylate G-CSF(lenograstim) 263 µg, days 12 until
      absolute neutrophil count &gt;1x10 9 /L SC

      The patients younger than 65 years that is possible, will done an autologous transplantation
      with peripheral stem blood cells or combined with peripheral stem blood cells and bone marrow
      stem cells. The preparative regimen recommended are BuCy2 (busulfan-cyclophosphamide) and
      ICT-Cy (irradiation corporal total-cyclophosphamide).

      The patients older than 65 years will receive one intensification cycle with carboplatin and
      G-CSF.

      The peripheral blood stem cells collection should be done during the recuperation period
      after consolidation chemotherapy in patients under 65 years. The leucapheresis procedure
      could be determinate for in each center participating.

      The patients with no sufficient collection of stem cells during the regeneration period
      post-chemotherapy of consolidation, will receive glycosylate G-CSF (lenograstim,
      Granocyte®)10 µg/kg/d SC during 5 days, doing the collection cells on days 5 and 6. In the
      situations that the peripheral blood stem cells are non satisfactory, will realize a
      collection of bone marrow stem cells.

      The realization of Peripheral Blood Stem Cell Transplantation or combined, depends the number
      of cells obtained in the collection procedures.In the situations that didn't reach sufficient
      number of cells (peripheral blood and bone marrow), should be administered one chemotherapy
      intensification cycle.

      The preparative regimen is established by each participating center, but is recommended one
      of next:

        1. BuCy2 (busulfan 16 mg/kg follow by cyclophosphamide 120 mg/kg),

        2. Total-body irradiation 12 Gy and cyclophosphamide 120 mg/kg.

      Intensification treatment:

      Patients older than 65 years and younger than 65 who the collection cells for transplantation
      is not enough, will receive one cycle of intensification chemotherapy with carboplatin and
      glycosylate G-CSF:

      Carboplatin 300 mg/m2/d days 1 to 4 IV in 24 hours continuous perfusion glycosylate G-CSF
      (lenograstim)263 µg f days 11 until absolute neutrophil count &gt;1x10 9 /L, SC
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of efficacy of study treatment: complete remission rate, remission duration and global survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of neutropenia and thrombocytopenia duration post-induction chemotherapy</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determinate the percentage of patients that reach the transplantation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determinate the toxicity of induction regimen and the chemotherapy postremission</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Acute Myeloblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt; 75 years

          -  Diagnosis of Myelodysplastic Syndrome in order to FAB criteria, excluding patients
             with chronic myeloid leukemia.

          -  IPI &gt; 1 (High risk or Intermedia risk-2) and/or IPE equal or &gt; 3 (High risk o
             Intermedia risk) or secondary acute myeloid leukemia.

          -  Resolved toxicity for previous treatments received to Myelodysplastic Syndrome .

          -  Myelodysplastic Syndrome de novo.

        Exclusion Criteria:

          -  Associated neoplasia.

          -  Chronic disease that can limit the patient follow up protocol (cardiovascular disease,
             active infection uncontrolled, etc.).

          -  Age &lt; 55 years with related donor HLA compatible.

          -  Use an investigational drug in the 30 previous days.

          -  Previous treatment with chemotherapy agents.

          -  Simultaneous treatment during the study with other drugs not allowed in the protocol.

          -  Bilirubin &gt; 2 mg/dL and GPT &gt;2 times the normal value.

          -  Creatinine &gt; 2 mg/dL.

          -  Hypersensibility to agents used in the protocol.

          -  Secondary MDS to chemo-radiotherapy .

          -  HIV positive.

          -  Chronic myeloblastic leukemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanz Guillermo, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanz Miguel Angel, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Fe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de la Ribera</name>
      <address>
        <city>Alzira</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del SAS</name>
      <address>
        <city>Jerez de la Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Leon</name>
      <address>
        <city>Leon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Pesset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.aehh.org</url>
    <description>Spanish association of Haematology</description>
  </link>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2007</study_first_submitted>
  <study_first_submitted_qc>June 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2007</study_first_posted>
  <last_update_submitted>November 17, 2008</last_update_submitted>
  <last_update_submitted_qc>November 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Josep Mª Ribera. Executive Secretary</name_title>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Peripheral blood stem cells transplantation</keyword>
  <keyword>Bone marrow transplantation</keyword>
  <keyword>Secondary Acute Myeloblastic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

